ASH Updates on SoC in Lymphomas: How Beneficial Are Newly Approved BT + Polatuzumab & Tafa + Len in R/R DLBCL? Are Bispecific Antibodies Active in B-NHL?

153 views
March 7, 2021
0 Comments
Login to view comments. Click here to Login
6th Annual Updates from ASH 2020